We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda’s Pevonedistat Disappoints in Late-Stage Cancer Trial
Takeda’s Pevonedistat Disappoints in Late-Stage Cancer Trial
Takeda Pharmaceutical said that its investigational cancer drug pevonedistat did not meet the primary endpoint of event-free survival in a phase 3 clinical trial.